crinetics team

About

Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. We have assembled a seasoned team with extensive expertise in drug discovery and development in endocrine G-protein coupled receptors (GPCRs) and built a highly productive drug discovery organization.

We have discovered a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide GPCRs to treat a variety of rare endocrine diseases where treatment options have significant efficacy, safety and/or tolerability limitations.

Our lead product candidate, CRN00808, is currently in clinical development for the treatment of acromegaly, and we are advancing additional product candidates through preclinical studies in parallel.

Our vision is to build the leading endocrine company which consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives.


  1. Gina Ford

    Gina Ford joined as VP, Corporate Strategy and Commercial Planning


  2. ACROBAT EVOLVE
    and EDGE Begin

    ACROBAT EVOLVE and EDGE Begin


  3. IPO

    Completed $117 million IPO on NASDAQ


  4. Alan Krasner

    Alan Krasner joined as CMO


  5. Phase 1
    Results

    Reported initial results from Phase 1 study of CRN00808


  6. Series B

    Completed $63.5 million Series B financing


  7. Marc Wilson

    Marc Wilson joined as CFO


  8. Phase 1
    Study

    Initiated Phase 1 Study of CRN00808 for acromegaly


  9. $2.4m Grant

    Awarded $2.4 million in SBIR grants for discovery of small molecule therapies targeting Cushing’s disease and hyperinsulinemic hypoglycemia


  10. $2.8m Grant

    Awarded $2.8 million SBIR Phase IIb grant for development of small molecule therapy for acromegaly


  11. Ajay Madan

    Appointed Ajay Madan as VP, Development


  12. Series A

    Completed $40.0 million Series A financing


  13. $1.5m Grant

    Awarded $1.5 million Phase II SBIR grant for discovery of kisspeptin antagonists for women’s health


  14. $2.2m Grant

    Awarded $2.2 million Phase II SBIR grant for discovery and development of a small molecule therapy for acromegaly


  15. FAF Grant
    Awarded

    Awarded first of two grants from Michaelson Prize and Grant Program to investigate veterinary reproductive health


  16. First Lab

    First Crinetics laboratory opened


  17. Phase 1 Grant

    Awarded Phase I SBIR grant to study GPCR biosensors


  18. Incorporated

    Crinetics is incorporated